Abbott Inks Exclusive Licensing Deal with Institut Curie for Bladder Cancer Biomarker | GenomeWeb

This article has been updated from a previous version to retract information originally provided by Abbott in a statement.

NEW YORK (GenomeWeb) – Abbott today announced that it has signed an exclusive licensing agreement with the Institut Curie for a biomarker for bladder cancer.

Genetic mutations in FGFR3 can be used for early detection, disease monitoring, and predicting patient outcomes in both urine and tissue-based testing. FGFR3 gene mutations are seen in about 70 percent of low-grade and 15 to 20 percent of high-grade bladder cancer cases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.